Riverstone Holdings, a Malaysian company founded by Wong Teek Son and Lee Wai Keong in 1991, has evolved from a glove chlorination service to a global leader in cleanroom gloves. The company, which achieved integrated cleanroom glove production in Asia and pioneered nitrile cleanroom glove manufacturing in Malaysia by 1995, is now quietly benefiting from the artificial intelligence (AI) boom. As of March 31, 2026, Riverstone held approximately RM700 million in net cash with no debt.
The company manufactures two main types of gloves: healthcare gloves and cleanroom gloves. While healthcare gloves account for about 80% of production capacity, they have thin margins due to high competition. In contrast, cleanroom gloves, which protect sensitive products like semiconductor wafers from contamination, corrosion, and static charge, contribute approximately 70% of the group's gross profit despite making up only 20% of production capacity. Riverstone's cleanroom gloves are crucial for manufacturers in the hard disk drive and semiconductor industries, which are vital for the data infrastructure supporting the modern economy.
The AI infrastructure expansion, particularly the development of data centers for large language models, has significantly increased demand for high-density data storage. This resurgence has prompted Riverstone's major hard disk drive customers to increase capacity, utilizing technologies like heat-assisted magnetic recording that require precise manufacturing environments where cleanroom gloves are essential. Although post-pandemic oversupply has pressured pricing in the healthcare glove sector, Riverstone has responded by focusing on customized healthcare products with better margins. The company aims for durable differentiation rather than dramatic growth, consistently paying out about 100% of earnings plus a special dividend equivalent to annual depreciation to shareholders.
Separately, Hartalega Holdings Bhd, another major glove manufacturer, announced a RM250 million capital expenditure for technological upgrades, automation, and AI across its production lines. Of this, RM235 million is for production technology and scaling proof-of-concept projects, and RM15 million is for AI-driven systems. This investment is aimed at increasing operational efficiency and competitiveness against Chinese manufacturers. Hartalega's CEO, Kuan Mun Leong, stated that this capex is not for new lines but for technology upgrades. The company plans to recommission Plant 3 by the end of 2026 and Plant 4 by the end of 2027, with anticipated headcount reductions of 50% and an 8% output increase per line at Plant 3 following upgrades. Hartalega currently operates with a plant utilization rate above 90% and plans to add a minimum of 9 billion pieces in production capacity from Plants 3 and 4, complementing its current capacity of 37 billion pieces. Hartalega also has plans for mergers and acquisitions to diversify and build a regional medical device distribution company, aiming to reduce risks associated with being solely an OEM glove producer in Malaysia.
